The role of lymphovascular invasion as a prognostic factor in patients with lymph node-positive operable invasive breast cancer.
The role of lymphovascular invasion as a prognostic factor in patients with lymph node-positive operable invasive breast cancer.
复制标题
DOI：
10.4048/jbc.2011.14.3.198
复制
发表时间：
2011-09
影响因子：
2.4
通讯作者：
Jegal YJ
中科院分区：
文献类型：
--
作者：
Song YJ;Shin SH;Cho JS;Park MH;Yoon JH;Jegal YJ
淋巴结阴性的浸润性乳腺癌患者中，血管浸润（LVI）是一个重要的预后因素。然而，LVI对淋巴结阳性乳腺癌患者的预后价值尚不清楚，且存在争议。因此，我们报告了一项对淋巴结阳性浸润性乳腺癌患者的大型队列研究中LVI预后意义的分析。我们回顾性分析了2004年1月至2007年12月在我院接受手术治疗的967例浸润性乳腺癌患者。其中淋巴结阳性乳腺癌患者349例。我们评估了这些患者的临床和病理资料，并比较了存在和不存在左心室肥厚组的5年总生存率和无病生存率。中位随访时间为48个月（范围：12-78个月），患者平均年龄为48岁（范围：23-78岁）。192例（55%）肿瘤患者存在LVI，且与年龄≤40岁相关（p=0.009），高组织学-组织学分级（p=0.007），雌激素受体状态（p=0.001），肿瘤大小≥2 cm（p<0.001）和受累淋巴结数量（p<0.001），但与孕激素受体状态、HER 2状态、p53状态或肿瘤多样性无关。LVI是无病生存期（p<0.001）和总生存期（p=0.006）的重要独立预后因素。多变量分析显示，LVI（p=0.003）、受累淋巴结数量（≥4; p=0.005）和高组织学分级（II和III; p=0.02）是全组患者无病生存期和总生存期的独立显著预测因素。在本例中，我们证明LVI是淋巴结阳性的原发性浸润性乳腺癌患者预后不良的显著预测因子，LVI是预后不良的显著预测因子价值。因此，LVI应作为辅助化疗环境中的决策工具在治疗策略中加以考虑。
Lymphovascular invasion (LVI) is an important prognostic factor in patients with lymph node-negative patients with invasive breast cancer. However, the prognostic value of LVI it is unclear and controversial about its prognostic value in patients with lymph node-positive breast cancer patients. So, we report the an analysis of the prognostic significance of LVI in a large cohort study of patients with lymph node-positive patients with invasive breast cancer. We retrospectively reviewed 967 patients with invasive breast cancer that had undergone surgical treatment at our hospital, from January 2004 to December 2007. Among these thempatients, 349 patients with lymph node-positive breast cancer patients are were included in this study. We evaluated clinical and pathological data in these patients, we compared with 5-year overall survival and disease-free survival between an LVI-present group and an LVI-absent group. The median follow-up was 48 months (range, 12-78 months), and the mean age of the patients was 48 years (range, 23-78 years). LVI was present in 192 patients (55%) of with tumors and was associated with age ≤40 years (p=0.009), high histologichistological grade (p=0.007), estrogen receptor status (p=0.001), tumor size ≥2 cm (p<0.001), and number of involved lymph nodes (p<0.001), but not with progesterone receptor status, HER2 status, p53 status, or tumor multiplicity. LVI was a significant independent prognostic factor for disease-free survival (p<0.001) and overall survival (p=0.006). By multivariate analysis revealed that LVI (p=0.003), number of involved lymph nodes (≥4; p=0.005), and high histological grade (II and III; p=0.02) was were an independent significant predictors of disease-free survival and overall survival in the whole group of patients. In this case, we demonstrated that LVI is a significant predictor of poor prognosis in patients with lymph node-positive patients with primary invasive breast cancer, LVI is a significant predictive predictor value of poor prognosis. So, LVI should be considered in the therapeutic strategy as a decision making tool in the adjuvant chemotherapy setting.
登录
查看更多内容
影响因子：
5.6
作者：
Mohammed, Rabab A. A.;Martin, Stewart G.;Ellis, Ian O.
通讯作者：
Ellis, Ian O.
影响因子：
3.3
作者：
DAVIS, BW;GELBER, R;RUDENSTAM, CM
通讯作者：
RUDENSTAM, CM
影响因子：
6.2
作者：
Truong, PT;Berthelet, E;Olivotto, IA
通讯作者：
Olivotto, IA
影响因子：
8.4
作者：
de Mascarel, I;Bonichon, F;Trojani, M
通讯作者：
Trojani, M
影响因子：
2.6
作者：
Yildirim, Emin;Berberoglu, Ugur
通讯作者：
Berberoglu, Ugur